Economy/Home · Economy

Samsung Biologics to Fund Peptide Facility Acquisition and Songdo Plant 6 Construction Through Rights Offering

Samsung Biologics (207940) will raise funds through a rights offering to finance the acquisition of a polypeptide production facility and the construction of Songdo Plant 6. Shihan Investment & Securities evaluated the fundraising as meaningful in terms of mid- to long-term capacity expansion and en

Wooil Shim
Staff Reporter
8 min read
Samsung Biologics to Fund Peptide Facility Acquisition and Songdo Plant 6 Construction Through Rights Offering
CBC News

Samsung Biologics (207940) will raise funds through a rights offering to finance the acquisition of a polypeptide production facility and the construction of Songdo Plant 6. Shihan Investment & Securities evaluated the fundraising as meaningful in terms of mid- to long-term capacity expansion and entry into new businesses, rather than the short-term increase in share count.

Two fundraising purposes: facility acquisition and plant construction

Shihan Investment & Securities broadly divided the purposes of the rights offering into funds for acquiring another entity and facility funds. The acquisition funds will be used to purchase the polypeptide production facility, while the facility funds will go toward building Songdo Plant 6.

The expansion of the polypeptide business is interpreted as a strategy to respond to rapidly growing demand for peptide drugs, centered on GLP-1 class obesity treatments. The securities firm viewed positively that acquiring existing production facilities allows faster market entry than building a new plant from scratch.

Songdo Plant 6 begins in earnest... target capacity of 180,000 liters

Construction of Songdo Plant 6 is also beginning in earnest. Samsung Biologics plans to use 294.8 billion won of the facility funds to establish Plant 6, with a target production capacity of 180,000 liters. By adding a large-scale biopharmaceutical production facility, the company is structured to expand capacity in stages following its existing plants.

Shihan Investment & Securities interpreted the decision to begin construction of Plant 6 as something that can be linked to future order momentum. Considering the current order backlog and large-scale contract discussions underway with clients, the firm judged that the company is proactively moving to expand production capacity.

Rights offering size 4.9%... supply-demand burden limited

Analysts also noted that the burden of increased share count from the offering is relatively limited. The offering size is about 4.9% of existing total shares outstanding, and 59.4% of the new shares will be allocated to Samsung affiliates, suggesting the supply-demand burden will not be significant.

Shihan Investment & Securities summarized the key points of the rights offering as two: securing a new growth area through the acquisition of the polypeptide production facility, and officially commencing construction of the 180,000-liter Songdo Plant 6.

Expected ex-rights price of about 1.58 million won as the benchmark

In terms of share price, volatility may occur after the announcement due to dilution concerns. However, Shihan Investment & Securities presented an expected ex-rights price of about 1.58 million won, calculated based on the stock price on the 27th, as a benchmark, and offered the view that if the share price falls significantly below this level, it could be interpreted as an excessive correction beyond the dilution effect of the offering.

Going forward, the timing of when the polypeptide facility acquisition translates into actual new revenue, the construction and operation schedule of Songdo Plant 6, and whether large-scale contract development and manufacturing organization (CDMO) contracts are secured are expected to serve as key variables in gauging Samsung Biologics' mid- to long-term corporate value.

[※ This article is an informational piece based on publicly disclosed corporate filings and securities firm analysis materials, and does not guarantee the purchase, sale, or investment returns of any specific stock. Securities firms' outlooks and analyses may change depending on future corporate performance and market conditions, and the final judgment and responsibility for investments rest with the investor. This article was written with AI assistance.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.